<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122039</url>
  </required_header>
  <id_info>
    <org_study_id>s64740</org_study_id>
    <nct_id>NCT05122039</nct_id>
  </id_info>
  <brief_title>ProspectIve Cohort psoriASiS fOllow-up (PICASSO)</brief_title>
  <acronym>PICASSO</acronym>
  <official_title>ProspectIve Cohort psoriASiS fOllow-up (PICASSO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the PICASSO-project is to facilitate future psoriasis-research in&#xD;
      dermatology. This register biobank will enable us to perform research in the field of&#xD;
      metabolomics, mRNA-expression, cardiovascular impact and the microbiome. The final aims are&#xD;
      patient stratification, better insight in disease-evolution and improved understanding of&#xD;
      markers that predispose to severe disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PICASSO-project is a prospective register with extensive biobanking in which patients&#xD;
      with a recent onset of psoriasis (&lt;3 years) can be enrolled. Participants are followed for a&#xD;
      period of 10 years, with scheduled visits every 2.5 years. The same protocol is followed for&#xD;
      every visit. The registry captures patient demographics, medical history (personal and&#xD;
      family), details of psoriasis treatment (previous and current), physical examination, disease&#xD;
      activity scores and PROMs. Some patients (substudy) will undergo ultra-sound to determine&#xD;
      carotid intima media thickness. Biobanking in this project encompasses extensive biosampling&#xD;
      of multiple tissues. It is not within the scope of this project to administer study&#xD;
      medication: patients receive standard of care treatment as prescribed by their physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">October 19, 2032</completion_date>
  <primary_completion_date type="Anticipated">October 19, 2032</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Disease evolution and bio-markers</measure>
    <time_frame>10 years</time_frame>
    <description>To link disease evolution (pasi, bsa, pga) to biologic markers</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Psoriasis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patient visits are planned at baseline and after 2.5, 5, 7.5 and 10 years. At all time-points&#xD;
      clinical examination and parameters, anamnesis, clinical pictures and questionnaires will be&#xD;
      completed. The following samples will be taken at all time-points:&#xD;
&#xD;
        -  Blood (serum, plasma, DNA)&#xD;
&#xD;
        -  Skin tape stripping (psoriatic and healthy skin)(mRNA-analysis)&#xD;
&#xD;
        -  Skin swabs (psoriatic and healthy skin)(skin microbiome)&#xD;
&#xD;
        -  Nails (DNA-analysis)&#xD;
&#xD;
        -  Faecal samples (faecal microbiome)&#xD;
&#xD;
        -  Saliva samples (mRNA-analysis, oral microbiome)&#xD;
&#xD;
        -  Urine samples (metabolomics)&#xD;
&#xD;
      The following examinations are optional:&#xD;
&#xD;
        -  Skin biopsy&#xD;
&#xD;
        -  Hair sample&#xD;
&#xD;
        -  Carotid Intima Media thickness (ultra-sound)&#xD;
&#xD;
        -  Examination of the oral cavity&#xD;
&#xD;
        -  Ocular swab (ocular microbiome)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Psoriasis patients with disease duration less than three years, aged 12-70 years old at&#xD;
        time of inclusion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical signs of Psoriasis since &gt;3 years&#xD;
&#xD;
          -  adults (70 years old or less) and children (&gt;12 years old)&#xD;
&#xD;
          -  willing and able to understand and sign the informed consent (plus legal&#xD;
             representative in case of a minor)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unwilling or unable to understand and sign the informed consent&#xD;
&#xD;
          -  disease duration longer than 3 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Hillary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom Hillary, MD</last_name>
    <phone>+3216337950</phone>
    <email>tom.hillary@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom M Hillary, MD</last_name>
      <phone>+3216337950</phone>
      <email>tom.hillary@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Tine Vanhoutvin</last_name>
      <phone>+3216337865</phone>
      <email>tine.vanhoutvin@uzleuven.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared. Data on cohort-level will be published.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

